These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 26614409)
1. Rational design, synthesis and in vitro evaluation of allylidene hydrazinecarboximidamide derivatives as BACE-1 inhibitors. Jain P; Wadhwa PK; Rohilla S; Jadhav HR Bioorg Med Chem Lett; 2016 Jan; 26(1):33-7. PubMed ID: 26614409 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and in vitro evaluation studies of sulfonyl-amino-acetamides as small molecule BACE-1 inhibitors. Jain P; Wadhwa PK; Gunapati S; Jadhav HR Bioorg Med Chem; 2016 Jun; 24(11):2567-2575. PubMed ID: 27102162 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of tasiamide B derivatives as BACE1 inhibitors. Liu J; Chen W; Xu Y; Ren S; Zhang W; Li Y Bioorg Med Chem; 2015 May; 23(9):1963-74. PubMed ID: 25842365 [TBL] [Abstract][Full Text] [Related]
4. 4-Oxo-1,4-dihydro-quinoline-3-carboxamides as BACE-1 inhibitors: synthesis, biological evaluation and docking studies. Liu P; Niu Y; Wang C; Sun Q; Zhai Y; Yu J; Sun J; Xu F; Yan G; Huang W; Liang L; Xu P Eur J Med Chem; 2014 May; 79():413-21. PubMed ID: 24763262 [TBL] [Abstract][Full Text] [Related]
5. Study on the active mechanism of β-secretase inhibitors by molecular simulations. Tian YL; Lv M; Li JJ; Xu T; Zhai HL; Zhang XY Eur J Pharm Sci; 2015 Aug; 76():138-48. PubMed ID: 25965961 [TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis and Evaluation of 2,4,6-substituted Pyrimidine Derivatives as BACE-1 Inhibitor: Plausible Lead for Alzheimer's Disease. Jain P; Wadhwa PK; Jadhav HR Med Chem; 2021; 17(10):1194-1206. PubMed ID: 33349218 [TBL] [Abstract][Full Text] [Related]
7. Alzheimer's disease: identification and development of β-secretase (BACE-1) binding fragments and inhibitors by dynamic ligation screening (DLS). Fernández-Bachiller MI; Horatscheck A; Lisurek M; Rademann J ChemMedChem; 2013 Jul; 8(7):1041-56. PubMed ID: 23757181 [TBL] [Abstract][Full Text] [Related]
8. Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads. Huang Y; Strobel ED; Ho CY; Reynolds CH; Conway KA; Piesvaux JA; Brenneman DE; Yohrling GJ; Moore Arnold H; Rosenthal D; Alexander RS; Tounge BA; Mercken M; Vandermeeren M; Parker MH; Reitz AB; Baxter EW Bioorg Med Chem Lett; 2010 May; 20(10):3158-60. PubMed ID: 20399652 [TBL] [Abstract][Full Text] [Related]
9. Structure-based design of novel dihydroisoquinoline BACE-1 inhibitors that do not engage the catalytic aspartates. Bowers S; Xu YZ; Yuan S; Probst GD; Hom RK; Chan W; Konradi AW; Sham HL; Zhu YL; Beroza P; Pan H; Brecht E; Yao N; Lougheed J; Tam D; Ren Z; Ruslim L; Bova MP; Artis DR Bioorg Med Chem Lett; 2013 Apr; 23(7):2181-6. PubMed ID: 23465612 [TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of novel 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridines as small molecule BACE-1 inhibitors. Razzaghi-Asl N; Firuzi O; Hemmateenejad B; Javidnia K; Edraki N; Miri R Bioorg Med Chem; 2013 Nov; 21(22):6893-909. PubMed ID: 24113238 [TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of 1,4-dihydropyridine derivatives as BACE-1 inhibitors. Choi SJ; Cho JH; Im I; Lee SD; Jang JY; Oh YM; Jung YK; Jeon ES; Kim YC Eur J Med Chem; 2010 Jun; 45(6):2578-90. PubMed ID: 20303626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]